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Serotonin and the renal blood supply: role of prostaglandins and the
SHT-2 receptor. Serotonin (5HT) has been reported to increase, to
decrease, or not to change renal blood flow. We postulated that
prostaglandin release in response to SHT acted as a confusing variable,
and tested the hypothesis by comparing infusions of serotonin and
angiotensin into one renal artery of 14 anesthetized dogs before and
after indomethacin administration. Renal blood flow (Q, by EM flow-
meter) responses to 5HT were routinely biphasic, an initial sharp
decrease followed by a gradual increase which stabilized well above
baseline at three to six minutes. Indomethacin, 1 to 2 mg/kg, did not
alter the acute Q decrement induced by 5HT but abolished the increase
in Q at three to six minutes (P < 0.001). Instead, sustained vasocon-
striction became apparent. Ketanserin reversed the sustained vasocon-
strictor effect of 5HT in indomethacin—treated dogs, leading to striking,
serotonin—induced vasodilatation. The latter vasodilatation in turn was
inhibited by methysergide. Four independent elements, two promoting
vasoconstrictjon and two vasodilatation, are suggested. One vasodila-
tar response is abolished by prostaglandin synthetase inhibition and the
other by methysergide, a complex 5HT receptor blocker. The sustained
vasoconstrictor response is blocked by ketanserin, suggesting an action
on the 5HT-2 receptor. The initial, transient vasoconstrictor response is
resistant to the blockers employed. fhese complex interactions may
account for the variability in reported responses of the renal blood
supply to serotonin.
There has been substantial interest in the renal action of
serotonin in the several decades since its discovery, but no
clear indication as to its action within the kidney, or its role in
pathogenesis [1]. In part the difficulty in defining its role has
reflected the wide variation in reports on both the direction and
magnitude of the renal vascular response, some investigators
reporting a net increase in renal blood flow [2, 3], whereas
others reported vasoconstriction [4—6], or no change despite the
use of substantial doses [7—9]. The recognition that local pros-
taglandin release modulates the renal vascular response to
vasoconstrictor hormones such as norepinephrine and angio.
tensin [10, II] led to one working premise in this study.
The development of a 5H'l'-2 receptor antagonist has clarified
many of serotonin's vascular actions: where serotonin induces
vasoconstriction, the response has been blocked by ketanserin,
the 5HT-2 antagonist [12—16]. This response differs from that
seen with serotonin antagonists available hitherto, which lack
selectivity for the 5HT-2 receptor and often have partial agonist
action.
In this study we describe four components in the canine renal
vascular response to serotonin, two leading to net vasodilata-
tion, and two resulting in vasoconstriction. Vasodilator effects
were sensitive to indomethacin and methysergide, but not to
ketanserin, while the dominant constrictor mechanism, evident
only after prostaglandin synthetase inhibition, is reversed by
ketanserin, the 5HT-2 antagonist.
Methods
Studies were performed on 14 mongrel dogs. They were
anesthetized with sodium pentobarbital, 30 mg/kg i.v., the
trachea was intubated and ventilation was supported. Each dog
received one liter of normal saline i.v. in the hour after
induction to replace losses due to surgery. Animals used in this
study were maintained in accordance with the guidelines of the
Committee on Animals of the Harvard Medical School and
those prepared by the Committee on Care and Use of Labora-
tory Animals of the Institute of Laboratory Animal Resources,
National Research Council.
Pressure and flow measurements
A 5 to 5.6 French polyethylene catheter was placed in a
superficial femoral artery and was directed to a selective renal
arterial position under fluoroscopic guidance. Through a flank
incision, a 3.0 to 3.5 mm diameter electromagnetic flow probe
connected to a SP2202 Statham—Gould Flowmeter (Statham
Instruments, Oxnard, California, USA) was placed on a renal
artery for measurement of mean and phasic blood flow. Test
injections of the contrast medium, meglumine diatrazoate, 60%
were used to document proper position of the catheter tip
relative to the flow probe. The catheter was kept open with a
constant infusion of normal saline, 2.5 mI/mm delivered by a
Holier RD074 pump. Delivery of test injections and infusions
were superimposed into this line to minimize injection artifacts
on the flow tracing. Mean arterial pressure was monitored using
a Statham P23DP pressure transducer connected to a Cordis
arterial sheath (Cordis Dow Corp., Miami, Florida, USA) in the
femoral artery. Pressures and flows were recorded continuously
on a Grass Polygraph.
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Protocols
Renal action of 5HT. Dose response relationships for intra-
renal injections or infusions of 5HT were defined in eight dogs.
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For the studies made with bolus injections, 0.02, 0.2 and 2.0 g
were delivered into the renal artery as a bolus by adding each to
the constant infusion in volumes of 0.1 ml. Thereafter, constant
infusions of 5HT at 3 and 30 sg per minute were made. The
latter dose produced the largest change in renal blood flow
without alterating systemic arterial blood pressure. Because the
renal vascular response to 5HT was biphasic. both for injec-
tions (Fig. I). and infusions (Fig. 2) dose response relationships
were defined by employing the nadir blood flow value during the
first vasoconstrictor phase, lasting 0 to 30 seconds, and the
maximum value during the second or dilator phase (about two
to three minutes) in the eight dogs.
During pilot studies, it was apparent that neither the response
to 5HT delivered as a bolus or by infusion was modified by
either ketanserin or methysergide, the SHT antagonists (data
not shown). Accordingly, the response to injections and infu-
sions of 5HT were examined in the same eight dogs 40 minutes
after the intrarenal administration of indomethacin (1.0 mg/kg).
The renal blood flow response to intrarenal injections of
sodium arachidonate (200 to 1,000 g) was used to verify
blockade of prostaglandin synihetase in these experiments. The
baseline response to sodium arachidonate was an increase in
renal blood flow of 63 8 mI/mm; it was reduced to 12 4
mi/mm after indomethacin (P < 0.001).
Comparison with angiotensin II. Intrarenal infusions of a
single dose of serotonin (Fig. 3A) and angiotensin II (Fig. 3B)
were compared before and after indomethaein in six additional
dogs. Four dogs received serotonin first, two received angio-
tensin 11 first. 5HT or All were infused for a period of 10
minutes. Renal blood flow values used for analysis were ob-
tained in the last minute prior to infusion of the test agent, 30
seconds, three minutes and six minutes after the onset of
action, The 5ff! dose used was 30 g/min. All was infused at
a rate aimed at producing a comparable initial fall in renal blood
flow to that produced by SHT. Arterial doses of All were 10
ng/min in two dogs and 30 ng/min in four dogs. Following
completion of baseline infusion studies, indomethacin was
administered as described for Protocol A. The 10 minute
infusions of 5HT and All were repeated in order to compare the
magnitude of the prostaglandin dependent component of renal
blood flow during administration of each agent.
A
100





0002 0.02 0.2 2.0
5HT bolus. g ia.
Fig. 1. Tracing of blood pressure (MAP) and renal blood flow (RBF)
response to serial doses oJ(5HT) injected into the renal artery. Note the




























Fig. 2A Dose—response relationships br renal blood flow when 5/IT
was injected into the renal artery as a bolos. Note the transient,
dose—related vasoconstriction, followed by dose—related vasodilatation.
B. Relationship between SHT close infused and the sustained increase in
















Fig. 3A. Tracing of the renal blood flow response to serotonin infused
into the renal artery. Note the initial, transient vasoconstriction fol-
lowed by sustained vasodilatation (top panel). In the same dog, after
treatment with indomethacin, note the sustained vasoconstriction re-
placing the secondary, vasodilator phase (middle panel). Administra-
tion of ketanserin did not modify the initial vasoconstrictor response to
serotonin, but blocked completely the sustained serotonin—induced
vasoconstriction (lower panel). B. The renal vascular response to
angiotensin infused into the renal artery prior to and (upper panel) and
following (lower panel) treatment with indomethacin.
Effect of 5HT antagonists after indomethacin. Although
ketanserin failed to modify renal vascular responses to 5HT in
the absence of indomethacin as noted above, the striking
influence of indomethacin on the renal vascular response to
5HT led us to re-examine the effect of 5HT antagonists on the
renal vascular response when complicating indomethacin—
responsive reactions had been blocked.
Ketanserin was administered intravenously in graded doses
from 10 to 1,000 rg/kg, and methysergide in graded doses from
100 to 1,000 pg/kg. Ketanserin was administered first to five
dogs, and methysergide was administered first to two dogs.
Three of the dogs which had received ketanserin then received
methysergide.
Baseline Q Q (10 see) Q (3 mm)
Pre IND 131 19 46 13** 196 29*
Post IND 115 15 30 8** 86 l5
P# NS NS 0.001
Infusions of 5HT were repeated 15 minutes after the admin-
istration of each antagonist.
Responses of renal blood flow to phenylephrine (1 to 30 pg)
injected into the renal artery were also made prior to and
following ketanserin and methysergide administration, in
search of evidence of alpha adrenergic blockade with the doses
employed.
Analysis. Infusion of both serotonin and angiotensin II pro-
duced transient changes in renal blood flow which were fol-
lowed by adjustments over the ensuing three to five minutes
(see tracings, Figs. 1 and 3). Analysis was therefore performed
by comparing baseline, 30 second, three minute and six minute
values of renal blood flow by ANOVA. Mean values are
presented with the standard error of the mean as the index of
dispersion. The null hypothesis was rejected when P was less
than 0.05.
Drugs. Indomethacin was provided by Merck, Sharp and
Dohme (West Point, Pennsylvania, USA). Serotonin creatinine
sulfate was obtained from Sigma Chemical Company (St.
Louis, Missouri, USA). Sodium arachidonate was prepared by
stirring arachidonic acid (Nu Check Prep Inc. Elysian, Minne-
sota, USA) in 100 mivi sodium carbonate under N2 gas.
Ketanserin was provided by Janssen Pharmaceuticals,
Piscataway, New Jersey. Methysergide was provided by San-
doz Pharmaceuticals, East Hanover, New Jersey. Drug doses
were calculated as the base rather than the salt.
Results
Protocol A. Renal actions of 5HT before and after
indo,nethacin
Mean arterial pressure was 137 8 mm Hg before interven-
tions and did not change significantly during serotonin admin-
istration in the doses used for analysis or after indomethacin
treatment.
The renal vascular response to bolus injections of 5HT was
complex, an initial vasoconstrictor response being followed by
a flow overshoot and a vasodilator response (Figs. 1 and 2).
Both the initial vasoconstrictor response and the delayed vao-
dilator response were dose—related after bolus injections with a
threshold response at a dose below 2.0 ng. Responses to doses
larger than 2 pg were not assessed because of complicating
systemic arterial hypotension.
During 5HT infusion the initial, vasoconstrictor response
strikingly resembled that seen during bolus injection (Fig. 3).
The secondary vasodilator response, however, differed in that
larger and more sustained renal blood flow increase occurred;
the relation between the 5HT dose infused and the sustained
5HT—after indomethacmflJ
Table 1. Comparison of renal blood flow responses to serotonin








Abbreviations are: Q, renal blood flow, mI/mm; IND, indomethacin;
#P for difference between pre- and post-indomethacin.
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Table 2. Effect of indomethacin on intrarenal bolus injections of
5HT

























* P < 0.05 vs. Phase 2 before indomethacin.
Values are renal blood flow from baseline in mI/mm, N = 8.
Table 3. Camparison of indomethacin effect on intrar
5HT and angiotensin II in six dogs
enally infused





141 23 68 7
149 15 69 8
139 17 78 10





Values are renal blood flow (mI/mm).
Symbol is: * P < 0.005 vs. LX Q 6 mm for 5 HT
increase in renal blood flow is shown in Figure 2B. Again, the
attempt to use larger doses produced hypotension.
Indomethacin administration converted the second vasodila-
tor phase following 5HT infusions to sustain vasoconstriction in
every case (Fig. 3A, Table 1). After three minutes of constant
infusion of 5HT at 30 micrograms per minute, for example,
indomethacin administration was responsible for a net differ-
ence of —110 7 mI/mm (P < 0.005). Indomethacin adminis-
tration did not influence the magnitude of the first, vaso-
constrictor phase.
Essentially similar effects were seen on the responses to
bolus injections of 5HT after indomethacin administration. No
alteration of the first phase of vasoconstriction was seen, but
significant blunting of the second, vasodilator phase was evi-
dent (Table 2).
Protocol B: Comparison with angiotensin
This protocol was designed to compare the influence of
indomethacin administration on the sustained renal vascular
response to angiotensin 11 and to serotonin in doses that
produced an initial renal blood flow fall in the neighborhood of
50%. Although indomethacin administration exerted a similar
directional influence on the sustained renal vascular response to
angiotensin (Fig. 3B) and to scrotonin (Fig. 3A), there were
quantitative differences in the response (Table 3). Tn both cases,
the vasoconstrictor response faded, but substantially more
rapidly and more completely during serotonin infusion than
during angiotensin II infusion. Six minutes after initiating
serotonin infusion, the absolute difference in blood flow to the
kidney was 112 26mI/mm when serotonin was employed, and
34 14 mI/mm when angiotensin II was employed (P< 0.005;
Table 3).
Table 4. Mean renal blood flow before at during
infusion and the influence of ketanserin and methysergide
N Baseline 30 Sec 6 Mm
1 5 141±18 69±5 106±26
I & K 5 130 15 39 10 181 30
I & M 5 169 32 102 40 165 32
Abbreviations are: I, indomethacin; K, ketanserin; M, methysergide.
Symbols are: * P < 0.005; ** P< 0.05.
Protocol C: The influence of serotonin antagonists
Neither ketanserin nor methysergide influenced the initial
serotonin—induced decrease in renal blood flow, but in indo-
methacin—treated dogs, ketanserin induced striking reversal of
the sustained vasoconstriction (Fig. 3A and Table 4).
Ketanserin's effect was complete in that a sustained increase of
renal blood flow above baseline was restored despite indometh-
acm pretreatment, with a threshold ketanserin dose of less than
1.0 sg/kg (Fig. 4).
The influence of ketanserin on the renal vascular response to
phenylephrine injected into the renal artery, as an index of
ketanserin's alpha adrenergic blocking action, is shown in
Figure 5. Phenylephrine when employed without inhibitors
induced a dose—related reduction in renal blood flow.
Ketanserin at a dose of 10 sg/kg had no influence on response,
but a dose of 100 pg/kg clearly blunted the renal vascular
response to phenylephrine (P < 0.01), Thus, the dose for alpha
blockade (Fig. 5) was substantially higher than the ketanserin
dose required to block the sustained renal vasoconstriction that
occurs during serotonin infusion following indomethacin (Fig.
4).
Further addition of methysergide, the nonselective 5HT
antagonist reduced the late increase in renal blood flow which
had been restored by ketanserin (Table 4), When methysergide
was employed alone after indomethacin, an intermediate re-
sponse was observed; a sustained increase of renal blood flow
above baseline did not occur. In the five animals which received
methysergide after indomethacin, there was no difference in
renal blood flow after six minutes of 5HT infusion from base-
line. The vasodilator response of 5HT had been abolished.
Neither ketanserin nor methysergide changed renal blood
flow when administered alone, in the basal state.
Discussion
These studies may clarify apparently divergent reports on the
complex renal vascular responses to serotonin [1—9, 17]. We
have identified two actions that result in net vasoconstriction
and two actions that result in net vasodilatation. The two
constrictor elements include immediate, transient, dose—related
vasoconstriction which was not modified by any maneuver
employed in the study, and a sustained element. The sustained
vasoconstriction was apparent only after prostaglandin synthe-
tase inhibition and was reversed by ketanserin, the 5HT-2
antagonist. In the intact dog, dose—dependent net vasodilatation
was the dominant response to serotonin, a response that
disappeared after prostaglandin synthetase inhibition. There
was clearly an additional vasodilator response unrelated to
prostaglandins that was apparent only after the administration
308 Blackshear et at
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of ketanserin; this vasodilator response was attenuated by
methysergide. Taken in all the data are compatible four sepa-
rable components in the renal vascular response, and the
pharmacological observations may account for three. Only the
initial, transient, dose—dependent vasoconstriction lacks a phar-
macological explanation. It is not surprising, therefore, that the
literature on the renal vascular response to serotonin has been
divergent.
One would anticipate from these observations, for example,
that studies in which a bolus of serotonin was employed would
reveal primarily vasoconstriction. This is compatible with many
reports [4—6]. Further, it might be expected that more sustained
infusions of serotonin would produce more variable results,
again as has been reported [7—11].
The ability of prostaglandin synthetase inhibitors to sensitize
the renal blood supply to angiotensin and to result in a more
sustained renal vascular response to angiotensin has been
widely documented [10, 11], and represents the paradigm of
modulation by prostaglandins of the response to vasoconstric-
tors. In this study that observation has been confirmed and
extended. The action of indomethacin on the response to
serotonin was similar in direction, but strikingly larger in
magnitude, whatever sequence was employed to administer the
two vasoconstrictor agents. Within seconds net vasodilatation
occurred with serotonin, whereas angiotensin's vasoconstrictor
response was better sustained in the same dogs. The most
straightforward explanation is that serotonin is more effective
than angiotensin in causing release of a vasodilator prostaglan-
din, although in the absence of a direct measurement of these
hormones the conclusion remains speculative. Although indo-
methacin is known to have a wide range of pharmacologic
actions [181, the parallelism between its influence on the re-




Fig. 5. Relation between phenylephrine dose injected into the renal
artery and change in renal blood flow. Note that ketanserin at 10 tg/kg
did not influence the response, but ketanserin at 100 jig/kg blunted the
response, reflecting alpha adrenergic blockade induced by ketanserin at
doses higher than those required for blockade of serotonin receptors.
Symbols are: (•) no inhibitors; (A) ketanserin 10 jig/kg; (0) ketanserin
100 jig/kg.
supports the obvious possibility that indomethacin acted by
virtue of that action in the study. Serotonin has been shown,
moreover, to induce prostaglandin release elsewhere [19].
The vasodilator effect of serotonin was substantial after
administration of ketanserin to the indomethacin—treated ani-
mals, suggesting a large, direct serotonin—mediated dilator
action, an action that is independent of either the 5HT-2
receptor or prostaglandins. This vasodilatation was reversed by
methysergide. Methysergide is a complex antagonist, having
substantial partial agonist, serotonin—like activity [20]. Under
the conditions of our experiment, however, the partial agonist
activity would have been anticipated to be vasodilator. It seems
more likely that methysergide was acting on an unrelated
serotonin receptor responsible for vasodilatation. We have
made similar observations on blood flow responses in the
circulation of the limb [15]. The term 5HT-1 receptor was
coined to apply to the central nervous system [21], and has not
hitherto been applied to responses in the circulation. Identical
actions of methysergide on dilator responses to serotonin in two
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Fig. 4. Retajion between ketanserin dose and the difference in the
sustained renal response to 5HT infusion prior to and after indometh-
acm. The increase in renal blood flow reflects blockade of
serotonin—induced vasoconstriction, and the threshold ketanserin dose
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vessels under specialized conditions [221 raises the interesting
possibility that there is, indeed, a 5FIT-1 receptor in the
circulation which leads to vasodilatation. The contribution of
that mechanism to the magnitude of the dilator response differs
from vascular bed to vascular bed. In the limb, for example,
prostaglandin synthetase inhibition does not modify the dilator
response to serotonin; in that vascular bed a mechanism re-
sponsive to methysergide accounted for all of the vasodilatation
[15].
Ketanserin is known to be an alpha—adrenergic blocking
agent, in addition to its ability to block 5HT-2 receptor,
although in general higher doses or concentrations are required
[16, 201. In this study, the ketanserin dose required to blunt
serotonin—induced renal vasoconstriction after indomethacin
was less than 1.0 j.sglkg, and there was little evidence of further
blockade with higher doses. The ketanserin dose required to
induce alpha—adrenergic blockade, with phenylephrine as the
index, was ten to 100—fold higher. it seems unlikely, therefore,
that the sustained renal vasoconstrictor response to serotonin
after indomethacin reflects an action of serotonin on alpha—
adrenergic receptors, It is also clear, if ketanserin is to be
employed as a pharmacologic probe to ascertain the role of 5HT
in syndromes characterized by renal vasoconstriction, that
consideration of dose will be important.
Serotonin—induced vasoconstriction was sufficient in degree
and was sufficiently well sustained to raise the possibility that it
could play a role in syndromes such as the hemolytic uremic
syndrome and some of the forms of inflammatory renal disease
in which platelet disruption and serotonin release occurs [23,
241. Among the strategies designed to reverse the potential
contribution of platelets to these syndromes, none have in-
cluded ketanserin, the 5HT-2 antagonist. Ketanserin antago-
nizes the vasoconstrictor properties of serotonin without antag-
onizing the vasodilator properties, a characteristic not shared
by the widely—studied serotonin antagonist, methysergide [15,
25]. Ketanserin, moreover, has a pronounced inhibitory influ-
ence on platelet aggregation, also apparently via the 5HT-2
receptor blockade [261.
Our data suggest that prostaglandins may ameliorate the
otherwise deleterious effects of serotonin on the renal circula-
tion. Spontaneous variation in the capacity of the kidney to
synthesize vasodilator prostaglandins, disease—related reduc-
tion in synthetic capacity or release, or pretreatment with
non-steroidal anti-inflammatory agents, may predispose to the
potentially destructive vasoconstrictor effects of serotonin.
Anti-inflammatory drugs are well documented to provoke renal
functional deterioration in patients with conditions associated
with ongoing intravascular platelet aggregation. Our observa-
tions may explain, for example, the manner in which patients
with active lupus nephritis or glomerulonephrisit of other etiol-
ogies are particularly susceptible to decreases in renal function
from indomethacin—like drugs [28, 291.
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